uveitis/diarrhea

Crohn's Disease Inflammatory bowel disease, encompassing Crohn's disease (CD) and ulcerative colitis (UC), represent incurable chronic inflammatory disorders of the intestinal tract. Patients with IBD experience a chronic relapsing and remitting course of their disease, with little ability to

1. Scientific rationale and general description: Nontuberculous mycobacteria (NTM) represent all mycobacteria not belonging to the Mycobacterium tuberculosis complex. This group of mycobacteria was discovered recently and has demonstrated pulmonary pathogenicity. The presence of a NTM in a

Patients are being asked to take part in this clinical research study because they have BRAF- or NRAS-mutated metastatic melanoma. If they participate they will receive the investigational drug nivolumab in combination with dabrafenib and/or trametinib based on their medical diagnosis, BRAF V600

Background: Tremelimumab is a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Anti-CTLA4 therapy has been shown to enhance anti-tumor immunity by blocking tumor-induced immune suppression of cytotoxic T cells. Durvalumab is a human monoclonal antibody directed

STUDY DESIGN - Screening - Assessment of the subject's eligibility to participate as determined by the inclusion/exclusion criteria. - Biopsy schedule - Subjects will be biopsied according to the schedule in Section 7. - Induction - The recommended induction dose of ipilimumab is 3 mg/kg

Crohn's disease is a chronic, inflammatory disorder (IBD) affecting any part of the gastrointestinal tract but frequently involves the small and large bowel. Typical presenting symptoms include abdominal pain and diarrhea. Patients with this disorder may also have extraintestinal manifestations

This was a Phase 2/3, multicenter, randomized, double-blind (DB), placebo-controlled, two-arm, efficacy, safety, and pharmacokinetic study designed to demonstrate the effectiveness of adalimumab in Japanese patients with moderate to severe Crohn's Disease (CD). All participants who had completed

Although corticosteroids remain the mainstay of therapy for intraocular inflammation, many patients are intolerant or resistant to corticosteroid therapy. In these patients, other immunosuppressive agents have been employed to control potentially sight-threatening uveitis. Nevertheless, ideal